Non-inferiority study of frexalimab subcutaneous administration compared to intravenous administration in adult participants with multiple sclerosis

Trial Identifier: EFC18098
Sponsor: Sanofi
Start Date: January 2026
Primary Completion Date: July 2027
Study Completion Date: November 2028
Condition: Multiple Sclerosis (MS)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
BELGIUM Bruges, BELGIUM, 8000
BELGIUM Kortrijk, BELGIUM, 8500
BELGIUM Overpelt, BELGIUM, 3900
UNITED STATES, Alabama Cullman, Alabama, UNITED STATES, 35058
UNITED STATES, Alabama Homewood, Alabama, UNITED STATES, 35209
UNITED STATES, Arizona Scottsdale, Arizona, UNITED STATES, 85253
UNITED STATES, California West Hollywood, California, UNITED STATES, 90048
UNITED STATES, Florida Altamonte Springs, Florida, UNITED STATES, 32714
UNITED STATES, Florida Naples, Florida, UNITED STATES, 34105
UNITED STATES, Florida Ormond Beach, Florida, UNITED STATES, 32174
UNITED STATES, Florida West Palm Beach, Florida, UNITED STATES, 33407
UNITED STATES, Georgia Smyrna, Georgia, UNITED STATES, 30080
UNITED STATES, Michigan Farmington Hills, Michigan, UNITED STATES, 48334
UNITED STATES, North Carolina Charlotte, North Carolina, UNITED STATES, 28210
UNITED STATES, North Carolina Raleigh, North Carolina, UNITED STATES, 27607
UNITED STATES, Tennessee Knoxville, Tennessee, UNITED STATES, 37922
UNITED STATES, Texas El Paso, Texas, UNITED STATES, 79912
UNITED STATES, Texas Plano, Texas, UNITED STATES, 75024